General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on January 16, 2002, from 10 a.m. to 12:30 p.m.

Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact: William Freas, or Sheila D. Langford, Center for Biologics Evaluation and Research (CBER) (HFM–17), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 19516. Please call the Information Line for up-to-date information on this meeting.

Agenda: On January 16, 2002, the committee will hear presentations relevant to the site visit report on the review of the research programs of the Laboratory of Bacterial, Parasitic, and Unconventional Agents, and the Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER.

Procedure: On January 16, 2002, from 10:00 a.m. to 10:45 a.m., and from 11:30 a.m. to 12:30 p.m. the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 9, 2002. Oral presentations from the public will be scheduled between approximately 11:30 a.m. to 12:30 p.m. on January 16, 2002. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 9, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On January 16, 2002, from 10:45 a.m. to 11:30 a.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss the reports of the review of individual research programs in the Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research.

FDA regrets that it was unable to publish this notice 15 days prior to the January 16, 2002, Blood Products Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Blood Products Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 26, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01–32253 Filed 12–27–01; 5:02 pm]

BILLING CODE 4160–02–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of Inspector General

Program Exclusions: November 2001

AGENCY: Office of Inspector General, HHS.

ACTION: Notice of program exclusions.

During the month of November 2001, the HHS Office of Inspector General imposed exclusions in the cases set forth below. When an exclusion is imposed, no program payment is made to anyone for any items or services(other than an emergency item or service not provided in a hospital emergency room) furnished, ordered or prescribed by an excluded party under the Medicare, Medicaid, and all Federal Health Care programs. In addition, no program payment is made to any business or facility, e.g., a hospital, that submits bills for payment for items or services provided by an excluded party. Program beneficiaries remain free to decide for themselves whether they will continue to use the services of an excluded party even though no program payments will be made for items and services provided by that excluded party. The exclusions have national effect and also apply to all Executive Branch procurement and non-procurement programs and activities.

Subject city, state	Effective date
Program-Related Convictions	
Bilenkin, Elana ..... Old Bridge, NJ	12/20/2001
Birdsong, Stacie ..... Detroit, MI	12/20/2001
Bitz, Jennifer M ..... Jamestown, ND	12/20/2001
Boguslavskiy, Vadim ..... Lavenel, NJ	12/20/2001
Brown, Maurice Chevale ..... Sterling, CO	12/20/2001
Dallakyan, Naira M ..... Pasadena, CA	12/20/2001
Greer, J Randall ..... Memphis, TN	12/20/2001
Gutman, Marci ..... Miami, FL	12/20/2001
Maddox, Yolanda Gail ..... Troy, AL	12/20/2001
McDonald, Anita Fletcher ..... Palestine, TX	12/20/2001
New York Health Plan ..... New York, NY	12/20/2001
Norman, Brigid ..... Riverdale, GA	12/20/2001
Paulin, John Gregory ..... Florence, CO	12/20/2001
Rapp, Donna Lynn ..... Lakewood, CO	12/20/2001
Reyes, Gloria ..... Miami, FL	12/20/2001
Rose, Melba L ..... Miami, FL	12/20/2001
Scarpitta, Janet ..... Newark, NJ	12/20/2001
Stolyar, Yelena ..... Golden, CO	12/20/2001
Taylor, Shirley Jean ..... Pearl, MS	12/20/2001
Urban, Edward J ..... Chargin Fall, OH	12/20/2001
Felony Conviction for Health Care	
Brathwaite, Stephen Earl ..... W Valley City, UT	12/20/2001
Burstein, Donald A ..... Warminster, PA	12/20/2001
Casiano, Janet ..... Carle Place, NY	12/20/2001
Fergusson, Olantungie Clarence ..... Sherman Oaks, CA	12/20/2001
Oldham, Susan G ..... Lexington, KY	12/20/2001
Runk, Lisa D ..... Wichita, KS	12/20/2001
Seals, Carlos V ..... Los Angeles, CA	12/20/2001
Felony Control Substance Conviction	
Davis, Donna K Kidd ..... Somerset, KY	12/20/2001
Gleason, Laura Jane ..... Phoenix, AZ	12/20/2001
Hendrick, Vickie ..... Gallatin, TN	12/20/2001
McMenamin, Deborah J ..... Carbondale, PA	12/20/2001
Sommer, Deborah Jane ..... Dayton, TX	12/20/2001
Patient Abuse/Neglect Convictions	
Barsuk, Joseph Jr ..... Churchville, NY	12/20/2001
Boykins, Loretta Penny ..... Baltimore, MD	12/20/2001
Cathey, Deborah	12/20/2001

Subject city, state	Effective date
Nashville, TN	
Coleman, Tracy Lavonne Laurora, CO	12/20/2001
Conyers, Leonard E Wilmington, DE	12/20/2001
Dickinson, Sharon Lee Corunna, MI	12/20/2001
Ferdon, Michael Kevin Ontario, OR	12/20/2001
Kegel, Alan Wheeling, IL	12/20/2001
Lembong, Noky Herems Diamond Bar, CA	12/20/2001
Maxian, Therese M Binghamton, NY	12/20/2001
Pawlak, Patricia Barker, NY	12/20/2001
Quinones, Anel Garfield, NJ	12/20/2001
Risley, Charles S Saugerties, NY	12/20/2001
Stocker, Charles Edward Lancaster, OH	12/20/2001
Thompson, Robert J Raymond, MS	12/20/2001
Watson, Marlene Maria Bronx, NY	12/20/2001
Conviction for Health Care Fraud	
Plyter, Mark Williamson, NY	12/20/2001
License Revocation/Suspension/ Surrendered	
Amundson, Terri Sue Lawrenceville, GA	12/20/2001
Banda-Orman, Selina Des Moines, IA	12/20/2001
Barolin, Linda Mantua, NJ	12/20/2001
Bealer, Mildred Sitch Pottsville, PA	12/20/2001
Bell, Donna S Douglas, AK	12/20/2001
Bryant, Laurie L Davenport, IA	12/20/2001
Burgess, Marleen K Cresco, IA	12/20/2001
Carico, Paula J Kendallville, IN	12/20/2001
Cigelske, Michael Allen Phoenix, AZ	12/20/2001
Duffie, Brenda L Burlington, IA	12/20/2001
Dykes, Judy R Phoenix, AZ	12/20/2001
Garrett, Herman Alpha Norcross, GA	12/20/2001
Harple, Carol Weiler Gordonville, PA	12/20/2001
Hernandez, Stephen Louis Hudson, FL	12/20/2001
Heuberger, Sally Sheffield, IA	12/20/2001
Hummell, Alan Cocoa, FL	12/20/2001
Jewkes, Mindy Salt Lake City, UT	12/20/2001
Kadish, William A Shrewsbury, MA	12/20/2001
Larson, Richard Warren Cherokee Village, AR	12/20/2001
Leonard, Rhonda Lynn Tyler, TX	12/20/2001
Long, Jill Suzanne W Blocton, AL	12/20/2001
Lucero, Glen M Denver, CO	12/20/2001
McGraw, Daniel P Haverhill, MA	12/20/2001
Milam, Stephen Robert Cicero, IN	12/20/2001
Moore, Jerry Gayle Houston, TX	12/20/2001
Newman, William T Chapel Hill, NC	12/20/2001
Petanovich, E John Emlenton, PA	12/20/2001
Peyton, Bret W Iowa Falls, IA	12/20/2001
Porter, Mary Jo Norfolk, VA	12/20/2001
Rice, Cynthia M Phoenix, AZ	12/20/2001
Richardson, Lawrence John Los Angeles, CA	12/20/2001
Rollins, Jane Michigan City, IN	12/20/2001
Shellhase, Barbara J Cleona, PA	12/20/2001
Spencer, Craig A Frankfort, IL	12/20/2001
Sugden, Mark F Virginia Beach, VA	12/20/2001
Tabotabo, Armando M Keyport, NJ	12/20/2001
Vail, Sheree Behr Malvern, PA	12/20/2001
Wehby, Michael Daniel Fort Thomas, KY	12/20/2001
West, Malynda Susan San Francisco, CA	12/20/2001
Fraud/Kickbacks	
Rousseau, Andre M Chicago, IL	09/10/2001
Entities Owned/Controlled By Convicted	
Arroyo Chiropractic Arroyo Grande, CA	12/20/2001
Carlin Chiropractic Health Ctr San Antonio, TX	12/20/2001
Cosmetic Surgery & Laser Inst Tustin, CA	12/20/2001
Gregory W Stephens, D C, P C Houston, TX	12/20/2001
Lund Chiropractic Arlington, TX	12/20/2001
Martin Family Chiropractic Ctr Cameron Park, CA	12/20/2001
Y & L Corporation Denver, CO	12/20/2001
Default on Heal Loan	
Alams, Humphrey A Jr Seattle, WA	12/20/2001
Anillo-Sarmiento, Manuel F Miami, FL	12/20/2001
Baron, Spencer H N Miami Beach, FL	12/20/2001
Bell, Robert E Phoenix, AZ	12/20/2001
Bornstein, Mark L Pembroke Pines, FL	12/20/2001
Buckingham, Guy M Orleans, MI	12/20/2001
Dauphin, Michelle M Pembroke Pines, FL	12/20/2001
Dinozzi, Anthony D Batavia, OH	12/20/2001
Dupuis, Edward J Dallas, TX	12/20/2001
Evans, Charla J Mobile, AL	12/20/2001
Ferguson, Camilla M Fairborn, OH	12/20/2001
Fredericks, Duane A Philadelphia, PA	12/20/2001
Fryer, Thomas J Ferron, UT	12/20/2001
Gilyot, Glenn David Sr New Orleans, LA	12/20/2001
Hansen, Hunter J Andrews, NC	12/20/2001
Havriliak, Stephen J Huntingdon Valley, PA	12/20/2001
Huber, Mark Princeton, MN	12/20/2001
Kardelis, Eugene C Jr Nazareth, PA	12/20/2001
Kardos, William P Apollo, PA	12/20/2001
Knott, Kevin Thomas Jr Oceanside, CA	12/20/2001
Kron, Kathy A Norton, MA	12/20/2001
Lallouz, Solomon Y Hollywood, FL	12/20/2001
Lantz, Larry S Broomall, PA	12/20/2001
Leavitt, Albert M Jr Alexandria, VA	12/20/2001
Legault, Michelle A Coon Rapids, MN	12/20/2001
Leon, Maria I Hollywood, FL	12/20/2001
Levy, Richard S Forthee, NJ	12/20/2001
Milbourne, Michael W Lafayette Hill, PA	12/20/2001
Milot, Sheila Inez Vernon Hills, IL	12/20/2001
Moore, Charles E Kansas City, KS	12/20/2001
O'Brien, Matthew P Romeo, MI	12/20/2001
Parenti, Lisa C Nashville, TN	12/20/2001
Parker, Melissa M Clinton, NC	12/20/2001
Parsons, Tien M Marathon, FL	12/20/2001
Payne, Carrol D Memphis, TN	12/20/2001
Pitts, Angela R Odessa, FL	12/20/2001
Powell, Michael N Wollaston, MA	12/20/2001
Pugh, Melvoria C Mobile, AL	12/20/2001
Ray, Donald Elton Orange Beach, AL	12/20/2001
Richichi, Mark S Ctr Moriches, NY	12/20/2001
Roberts, Pamela Charlotte, NC	12/20/2001

Subject city, state	Effective date
Robinson, Cynane Ann Yetta ... Southfield, MI	12/20/2001
Rodebaugh, Cheryl Lynn ..... Denver, CO	12/20/2001
Rose, Keith D ..... Big Rapids, MI	12/20/2001
Roudebush, Mark D ..... Cordova, TN	12/20/2001
Rouselle, Dionne Marie ..... Memphis, TN	12/20/2001
Rubinstein, David M ..... Tamarac, FL	12/20/2001
Schwirian, Jay A ..... White Oak, PA	12/20/2001
Smith, Terrance Herbert ..... Sioux Falls, SD	12/20/2001
Smith, William H III ..... Philadelphia, PA	12/20/2001
Sparks, Darlene V ..... Annandale, VA	12/20/2001
Stevens, Joanne K ..... Broadview Hgts, OH	12/20/2001
Strasser, Robert T ..... Lake Zurich, IL	12/20/2001
Thompson, Emma R ..... Lithonia, GA	12/20/2001
Van Brookhoven, Gloria ..... Atlanta, GA	12/20/2001
Vodvarka, James M ..... Steubenville, OH	12/20/2001
Webb, James R ..... Shawnee Mission, KS	12/20/2001
Wohlschlaeger, Michael Alan ... Panama City Bch, FL	12/20/2001
Wolf, Jacob M ..... Akron, OH	12/20/2001
Wright, Bill G ..... Lincoln, NE	12/20/2001
Yoder, Patricia L ..... Ocklawaha, FL	12/20/2001
Young-Cheney, Joan E ..... Creswell, OR	12/20/2001
Peer Review Organization Cases	
Hinkley, Bruce Stanton ..... Dallas, TX	11/14/2001

Dated: December 3, 2001.

Calvin Anderson, Jr.,

Director, Health Care Administrative Sanctions, Office of Inspector General.

[FR Doc. 01–32156 Filed 12–31–01; 8:45 am]

BILLING CODE 4150–04–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Peter A. Soukas, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7056 ext. 268; fax: 301/402–0220; e-mail: *soukasp@od.nih.gov.* A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

LL–37 is an Immunostimulant

Oleg Chertov (NCI), Joost Oppenheim (NCI), De Yang (NCI), Qian Chen (NCI), Ji Wang (NCI), Mark Anderson (EM), Joseph Wooters (EM)

Serial No. 09/960,876 filed 21 Sep 2001

This invention relates to use of an antimicrobial peptide as a vaccine adjuvant. LL–37 is the cleaved antimicrobial 37-residue C-terminal peptide of hCAP18, the only identified member in humans of a family of proteins called cathelicidins. LL–37/hCAP18 is produced by neutrophils and various epithelial cells. LL–37 is well known as an antimicrobial peptide. However, although antimicrobial peptides have generally been considered to contribute to host innate antimicrobial defense, some of them may also contribute to adaptive immunity against microbial infection. The inventors have shown that LL–37 utilizes formyl peptide receptor-like 1 (FPLR1) as a receptor to activate human neutrophils, monocytes, and T cells. Since leukocytes participate in both innate and adaptive immunity, the fact that LL–37 can chemoattract human leukocytes may provide one additional mechanism by which LL–37 can contribute to host defense against microbial invasion, by participating in the recruitment of leukocytes to sites of infection. The invention claims methods of enhancing immune responses through the administration of LL–37 alone, in conjunction with a vaccine, and methods of treating autoimmune diseases. The invention is further described in Chertov et. al., ''LL–37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells,'' J Exp. Med. 2000 Oct 2;192(7):1069–74.

A Method for Bioconjugation Using Diels-Alder Cycloaddition

Vince Pozsgay (NICHD)

Serial Number 09/919,637 filed 01 Aug 2001

This invention relates to a new method for the synthesis of conjugate vaccines using the Diels-Alder cycloaddition reaction to covalently attach a carbohydrate antigen from a pathogen to a protein carrier. The Diels-Alder reaction has not been extended to conjugation involving biopolymers or other types of polymeric materials. Advantages of this method are that cross-linking during conjugation is entirely avoided in addition to the mild chemical conditions under which this synthesis method proceeds. Diels-Alder reactions commonly take place in high-temperature environments; the method contemplated by this invention takes place at much lower temperatures. In addition to claiming methods of synthesis for conjugate vaccines using the Diels-Alder cycloaddition, the patent application claims vaccines produced utilizing the method, and methods of inducing antibodies which react with the polysaccharides contemplated by the invention.

Identification of New Small RNAs and ORFs

Susan Gottesman (NCI), Gisela Storz (NICHD), Karen Wassarman (NICHD), Francis Repoila (NCI), Carsten Rosenow (EM)

Serial No. 60/266,402 filed 01 Feb 2001

The inventors have isolated a number of previously unknown sRNAs found in E. coli. Previous scientific publications by the inventors and others regarding sRNAs have shown these sRNAs to serve important regulatory roles in the cell, such as regulators of virulence and survival in host cells. Prediction of the presence of genes encoding sRNAs was accomplished by combining sequence information from highly conserved intergenic regions with information about the expected transcription of neighboring genes. Microarray analysis also was used to identify likely candidates. Northern blot analyses were then carried out to demonstrate the presence of the sRNAs. Three of the sRNAs claimed in the invention regulate (candidates 12 and 14, negatively and candidate 31, positively) expression of RpoS, a major transcription factor in bacteria that is important in many pathogens because it regulates (amongst other things) virulence. The inventors' data show that these sRNAs are highly